BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 15867390)

  • 1. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation.
    Sabnis GJ; Jelovac D; Long B; Brodie A
    Cancer Res; 2005 May; 65(9):3903-10. PubMed ID: 15867390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
    Belosay A; Brodie AM; Njar VC
    Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
    Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A
    Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor, growth factor receptor and protooncogene protein activities and possible signal transduction crosstalk in estrogen dependent and independent breast cancer cell lines.
    Mohamood AS; Gyles P; Balan KV; Hollis VW; Eckberg WR; Asseffa A; Han Z; Wyche JH; Anderson WA
    J Submicrosc Cytol Pathol; 1997 Jan; 29(1):1-17. PubMed ID: 9066137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
    Jordan NJ; Gee JM; Barrow D; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model.
    Staka CM; Nicholson RI; Gee JM
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S85-97. PubMed ID: 16113102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in transforming growth factor-alpha and -beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth.
    Herman ME; Katzenellenbogen BS
    Cancer Res; 1994 Nov; 54(22):5867-74. PubMed ID: 7954416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
    Kijima I; Itoh T; Chen S
    J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
    Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
    Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth.
    Frogne T; Jepsen JS; Larsen SS; Fog CK; Brockdorff BL; Lykkesfeldt AE
    Endocr Relat Cancer; 2005 Sep; 12(3):599-614. PubMed ID: 16172194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells.
    Normanno N; De Luca A; Bianco C; Maiello MR; Carriero MV; Rehman A; Wechselberger C; Arra C; Strizzi L; Sanicola M; Salomon DS
    J Cell Physiol; 2004 Jan; 198(1):31-9. PubMed ID: 14584041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
    Kinoshita Y; Chen S
    Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling.
    Ravid D; Maor S; Werner H; Liscovitch M
    Oncogene; 2005 Feb; 24(8):1338-47. PubMed ID: 15592498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
    Sabnis G; Brodie A
    Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGF signaling activates STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells.
    Johnson MR; Valentine C; Basilico C; Mansukhani A
    Oncogene; 1998 May; 16(20):2647-56. PubMed ID: 9632141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.